Dallah Healthcare CoSAU:4004 92 EBITDA Margin % is 19.15% as of Mar. 2026, which is 11% below its 10-year median of 21.47. GuruFocus rates SAU:4004 with a GF Score™ of 92/100 and a GF Value™ of ﷼204.73 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Dallah Healthcare Co ranks better than 76.24% on this metric.
Dallah Healthcare Co (SAU:4004) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dallah Healthcare Co EBITDA Margin % Related Terms
Dallah Healthcare Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dallah Healthcare Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAU:4004 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Dallah Healthcare Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dallah Healthcare Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dallah Healthcare Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dallah Healthcare Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dallah Healthcare Co (SAU:4004) has a EBITDA Margin % of 19.15% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dallah Healthcare Co and its competitors. This is 11% below median its historical median of 21.47. Over the past decade, Dallah Healthcare Co's EBITDA Margin % has ranged from 19.55 to 30.26. According to the industry distribution chart, Dallah Healthcare Co ranks #158 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 23.8%.
Is Dallah Healthcare Co's EBITDA Margin % too high?
Dallah Healthcare Co's current EBITDA Margin % of 19.15% is 11% below median its 10-year median of 21.47. Over the past 10 years, this metric has ranged from a low of 19.55 to a high of 30.26. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Dallah Healthcare Co's value of 19.15% is 87% above this industry median. Based on the distribution chart, Dallah Healthcare Co ranks #158 out of 665 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Dallah Healthcare Co has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dallah Healthcare Co ranks #158 out of 665 companies for EBITDA Margin %. This places Dallah Healthcare Co in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.24. Dallah Healthcare Co's value of 19.15% is 87% above this benchmark. Historically, Dallah Healthcare Co's own EBITDA Margin % has ranged from 19.55 to 30.26 over the past decade. While the company's 10-year median is 21.47 vs. the industry median of 10.24, Dallah Healthcare Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dallah Healthcare Co's current EBITDA Margin % of 19.15% is 87% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dallah Healthcare Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dallah Healthcare Co's current EBITDA Margin % is 19.15%, which is 11% below median its own 10-year median of 21.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼204.73, compared to a current price of ﷼112.00 — trading 45.3% below its estimated fair value. The current EBITDA Margin % is 19.15%, which is 11% below median its 10-year median of 21.47 and 87% above the Healthcare Providers & Services industry median of 10.24. Dallah Healthcare Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current EBITDA Margin % is 19.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?
Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued.
The current stock price of ﷼112.00 is trading 45.3% below its estimated GF Value™ of ﷼204.73.
GuruFocus considers Dallah Healthcare Co to be Possible Value Trap.
Key valuation signals for SAU:4004:
EBITDA Margin %: 19.15% (11% below median its 10-year median of 21.47)
GF Value™: ﷼204.73 vs. price of ﷼112.00 (45.3% below fair value)
Industry Position: 87% above the Healthcare Providers & Services median (#158 of 665)
No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
92GF Score
Get the complete analysis for SAU:4004
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4004 has been successfully added to your 
